INTERACT4 Expansion - Validation Study (INTERACT4 Exp)
INTEnsive Ambulance-delivered Blood Pressure Reduction in Biomarker-identified Hyper-ACute Intracerebral Haemorrhage Trial - Validation Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Craig Anderson, MD
- Phone Number: +61 4039448107
- Email: canderson@georgeinstitute.org.au
Study Contact Backup
- Name: Cheryl Carcel, MD
- Email: ccarcel@georgeinsitute.org.au
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia
- Liverpool Hospital
-
Principal Investigator:
- Dennis Cordato
-
Contact:
- Cheryl Carcel
- Phone Number: +61 2 8052 4508
- Email: ccarcel@georgeinstitute.org.au
-
Sydney, New South Wales, Australia
- Royal North Shore Hospital
-
Contact:
- Cheryl Carcel
- Phone Number: +61 2 8052 4508
- Email: ccarcel@georgeinstitute.org.au
-
Principal Investigator:
- Christopher Partyka
-
Sydney, New South Wales, Australia
- Nepean Hospital
-
Contact:
- Cheryl Carcel
- Phone Number: +61 2 8052 4508
- Email: ccarcel@georgeinstitute.org.au
-
Principal Investigator:
- Sameen Haque
-
Sydney, New South Wales, Australia
- New South Wales Ambulance
-
Contact:
- Cheryl Carcel
- Phone Number: +61 2 8052 4508
- Email: ccarcel@georgeinstitute.org.au
-
Principal Investigator:
- David Patterson
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults (age ≥18 years);
- Acute syndrome that is due to presumed acute stroke, defined as FAST (Face, Arm, Speech, Time) scores of ≥2 with an arm motor deficit;
- Time ≤3 hours from last seen well;
- Systolic BP (SBP) ≥150mmHg.
Exclusion Criteria:
- Participants in coma (no response to tactile/verbal stimulation); or/and do not respond to "P" or "U" on the alert/verbal/painful/unresponsive (APVU) responsiveness scale;
- Severe known co-morbid disease (e.g. cancer, chronic airflow disease, severe dementia, severe heart failure, pre-existing disability [needing help]);
- Known history of epilepsy or seizure at onset;
- Recent head injury (where there is potential for another type of intracranial haemorrhage or head trauma);
- Hypoglycaemia (glucose<4.0 mmol/L) as measured in the ambulance.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of participants without ICH on hospital-based brain CT who are correctly identified as negative based on GFAP point-of-care measurement. (Specificity)
Time Frame: From enrolment to initial CT scan up until 7 day assessment
|
From enrolment to initial CT scan up until 7 day assessment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants with ICH on hospital-based brain CT who are correctly identified as positive based on GFAP point-of-care measurement.
Time Frame: From enrolment to initial CT scan up until 7 day assessment
|
From enrolment to initial CT scan up until 7 day assessment
|
|
|
Proportion of participants with a positive GFAP point-of-care measurement who are confirmed to have ICH on hospital-based brain CT.
Time Frame: From enrolment to initial CT scan up until 7 day assessment
|
From enrolment to initial CT scan up until 7 day assessment
|
|
|
Proportion of participants with a negative GFAP point-of-care measurement who are confirmed to not have an ICH on hospital-based brain CT.
Time Frame: From enrolment to initial CT scan up until 7 day assessment
|
From enrolment to initial CT scan up until 7 day assessment
|
|
|
Feasibility of recruitment, assessed by the proportion of enrolled participants over the number of stroke calls in the participating networks during the study period.
Time Frame: From enrollment to end of the study.
|
From enrollment to end of the study.
|
|
|
Feasibility of protocol delivery, assessed by the proportion of participants for whom all required study assessments in the ambulance were completed among those in whom assessments were initiated.
Time Frame: From enrolment to transfer to hospital at day 1
|
Study assesments include: participant screening, GFAP testing with the point-of-care device, and data entry
|
From enrolment to transfer to hospital at day 1
|
|
Feasibility of GFAP testing in the prehospital setting, defined as the proportion of enrolled participants in whom GFAP testing was successfully completed using the point-of-care device in the ambulance.
Time Frame: From enrolment to transfer to hospital at day 1
|
From enrolment to transfer to hospital at day 1
|
|
|
Correlation of GFAP measurement by the point-of-care device against a laboratory assay.
Time Frame: From enrolment to transfer to hospital at day 1
|
From enrolment to transfer to hospital at day 1
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity, specificity, positive predictive value, and negative predictive value for identifying ICH using a (+) GFAP combined with a (-) D-dimer result on the point-of-care device, compared with hospital-based brain CT.
Time Frame: From enrolment to initial CT scan up until 7 day assessment
|
Exploratory outcome
|
From enrolment to initial CT scan up until 7 day assessment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P01720
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.